Bio-Techne to Present at Investor Conferences

Rhea-AI Summary

CI&T (NYSE: CINT) has been recognized as a Leader in The Forrester Wave™: Modern Application Development (MAD) Services, Q1 2025 report. The company received the highest possible scores in nine evaluation criteria, including vision, agile custom development, and TuringBot accelerator services.

The report highlights CI&T's superior expertise in agile, DevSecOps, and MAD cultural change, particularly noting their excellence in transitioning clients from project to product-based working. A key differentiator is CI&T FLOW, their proprietary AI platform that integrates AI agents and humans, with 75% of their workforce engaging with it daily.

According to Bruno Guicardi, President and Co-Founder, this recognition reinforces their commitment to co-creating transformative solutions. The company's application modernization strategy focuses on driving continuous innovation while prioritizing efficiency and cost reduction through strong cloud platform partnerships.

MINNEAPOLIS, Feb. 27, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:

TD Cowen 45^th Annual Health Care Conference
March 4, 2025
2:30 PM EST

Leerink Partners Global Healthcare Conference
March 11, 2025
11:20 AM EDT

Barclays 27^th Annual Global Healthcare Conference
March 12, 2025
10:00 AM EDT

A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

Contact:  David Clair, Vice President, Investor Relations & Corporate Development
               david.clair@bio-techne.com
               612-656-4416

FAQ

What recognition did CI&T (NYSE: CINT) receive in the Forrester Wave report for Q1 2025?

CI&T was named a Leader in Modern Application Development Services, receiving top scores in nine criteria including vision and agile custom development.

How does CI&T's FLOW platform impact their development services?

CI&T FLOW is an AI platform that integrates AI agents with human developers, enhancing software development lifecycle productivity with 75% of workforce daily engagement.

What are the key strengths highlighted in Forrester's evaluation of CI&T?

Forrester highlighted CI&T's superior expertise in agile, DevSecOps, MAD cultural change, and excellence in both front-end and back-end development services.

What specific evaluation criteria did CI&T score highest in according to Forrester?

CI&T received highest scores in vision, agile custom development, project-to-product operating model, TuringBot accelerator services, architecture capabilities, and backend re-engineering.

How does CI&T approach application modernization for businesses?

CI&T focuses on continuous innovation through cloud platform partnerships, prioritizing efficiency, cost reduction, and measurable outcomes in their modernization strategy.